These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1447737)

  • 21. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P; White BP; Humphrey PP
    Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
    Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
    Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer.
    Muck S; Weber AA; Schrör K
    Eur J Pharmacol; 1998 Feb; 344(1):45-8. PubMed ID: 9570446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
    Krauss AH; Woodward DF; Burk RM; Gac TS; Gibson LL; Protzman CE; Abbass F; Marshall K; Senior J
    J Ocul Pharmacol Ther; 1997 Aug; 13(4):303-12. PubMed ID: 9261766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.
    Cimetière B; Dubuffet T; Landras C; Descombes JJ; Simonet S; Verbeuren TJ; Lavielle G
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1381-6. PubMed ID: 9871770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S; Nakahata N; Ohizumi Y
    Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
    Tymkewycz PM; Jones RL; Wilson NH; Marr CG
    Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta.
    Romstedt KJ; Shin Y; Shams G; Doyle K; Tantishaiyakul V; Clark MT; Adejare A; Hamada A; Miller DD; Feller DR
    Biochem Pharmacol; 1993 Dec; 46(11):2051-9. PubMed ID: 8267653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[[(4-chlorophenyl)sulfonyl]-amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists.
    Dack KN; Dickinson RP; Long CJ; Steele J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2061-6. PubMed ID: 9873486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
    Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
    J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
    Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
    Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.
    Rolin S; Dogné JM; Michaux C; Delarge J; Masereel B
    Prostaglandins Leukot Essent Fatty Acids; 2001 Aug; 65(2):67-72. PubMed ID: 11545621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
    Ohshima E; Takami H; Sato H; Obase H; Miki I; Ishii A; Karasawa A; Kubo K
    J Med Chem; 1992 Sep; 35(18):3394-402. PubMed ID: 1388207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L; Fitzgerald DJ; Fitzgerald GA
    J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel.
    Heinisch G; Holzer W; Kunz F; Langer T; Lukavsky P; Pechlaner C; Weissenberger H
    J Med Chem; 1996 Sep; 39(20):4058-64. PubMed ID: 8831771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.